The major cancer therapeutic modalities include surgery, chemotherapy and radiotherapy. Although these treatment regimens have played a significant role in effectively inhibiting cancer, their associated morbidity reduces the overall quality of life. Thus, researchers are striving to identify any alternate therapeutic approach capable of inhibiting cancer without eliciting the added morbidity. Among the alternate cancer therapeutics being researched, much importance is being given to the use of plants due to the presence of a wide variety of anti-carcinogenic compounds. Tinospora cordifolia (Tc) is one such plant and has shown to exhibit anti-carcinogenic properties. The present review aimed to systematically analyze published data on the effect of Tinospora cordifolia-derived phytocomponents on cancer. PubMed, Scopus, Web of Science, Embase and Cochrane library were searched using the keywords Tinospora cordifolia; anticancer; phytocomponents until March 20, 2019. In vivo and in vitro original studies in the English language were included. Of the 342 articles identified, only 25 articles met the selection criteria and were included in the review. Significant anti-carcinogenic properties were exhibited by Tinospora cordifolia-derived phytocompounds including palmative, berberine, new clerodane furanoditerene glycoside, arabinogalactan, phenolic compounds and epoxy cleodane diterpene. No significant side effects have been elicited with its use. Based on the data from the included studies, Tinospora cordifolia could be a natural therapeutic agent for cancer, provided its anti-carcinogenic properties can be elicited consistently at a large scale in clinical trials.

The intention of this review was to condense ongoing findings on the use of circulating DNAs from bodily fluids (blood, serum and plasma) as cancer biomarkers in patients with oral squamous cell carcinoma. Studies were collected after searching databases: PubMed and Google library. Additional search was performed through cross-check on the bibliography of selected articles. After the selection process made by two of the authors, articles which met the inclusion criteria were included in the review. Results revealed that circulating DNAs from blood, serum or plasma appear as favorable candidates as cancer biomarkers in patients suffering from oral cancer. The possibility to forecast recurrences and metastases through follow-up by quantification of candidate DNAs serve as another possible characteristic to be directed in forthcoming studies. However, methodological standardization and even sampling are required to increase the power and accuracy of results.

Es p16 marker. p16 (D9S1747) is a microsatellite marker which detects early changes in OSCC. To redefine more clearly the role of D9S1747 (p16 microsatellite marker) and its expression in OSCC, the study was designed with the aim to check the detection of D9S1747 in OSCC and to compare the same with histopathological grades and tumor node metastasis staging. Materials and Methods: Forty cases of paraffin-embedded tissue section which was histologically confirmed as OSCC and 10 cases of normal tissues were retrieved from the archives. DNA was extracted from the tissue sections and subjected for polymerase chain reaction to detect p16 microsatellite marker D9S1747. Data were analyzed using Chi-square test and Fisher's exact test. Results: Twenty-seven cases (67.5%) showed p16 microsatellite marker positivity for OSCC. It was observed that 44.4%, 51.9% and 3.7% p16 microsatellite markers were positive in Stage 1, Stage 2 and Stage 4 OSCC cases, respectively. p16 microsatellite marker positivity was found in 77.8%, 22.2% and 0% for well-differentiated, moderately differentiated and poorly differentiated OSCC cases, respectively. Conclusion: The observations of the present study revealed D9S1747 marker as an early event in OSCC, and this can be used as a prognostic marker....